For the quarter ended March 2024, Regeneron (REGN) reported revenue of $3.15 billion, down 0.5% over the same period last year. EPS came in at $9.55, compared to $10.09 in the year-ago quarter.The reported revenue represents a surprise of -1.53% over the Zacks Consensus Estimate of $3.19 billion. With the consensus EPS estimate being $10.20, the EPS surprise was -6.37%.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expe ...

Regeneron C or porat e P res ent at ion M A Y 2 0 2 4 This non-promotional presentation contains investigational data as well as forward-looking statements; actual results may vary materially. Note regarding forward-looking statements and non-GAAP financial measures Thispresentationincludesforward-lookingstatementsthatinvolverisksanduncertaintiesrelatingtofutureeventsandthefutureperformanceofRegeneronPharmaceuticals,Inc.("Regeneron"orthe"Company"),andactualeventsor resultsmaydiffermateriallyfromtheseforward ...

Financial Performance - Regeneron reported revenues of $3,145.0 million for the three months ended March 31, 2024, a decrease of 0.5% from $3,162.1 million in the same period of 2023[105]. - Net income for the quarter was $722.0 million, down 11.7% from $817.8 million year-over-year[105]. - Diluted net income per share decreased to $6.27, compared to $7.17 in the prior year, reflecting a decline of 12.5%[105]. - Revenues for the three months ended March 31, 2024, were $3,145.0 million, a decrease of 0.5% from $3,162.1 million in the same period of 2023[140]. - Net product sales for EYLEA in the U.S. decreased to $1,401.6 million, down 32.2% from $1,433.8 million year-over-year[142]. - Collaboration revenue from Sanofi increased to $909.8 million, up 13.9% from $798.4 million in the prior year[144]. - Regeneron's share of profits from Dupixent and Kevzara net product sales was $925.9 million, an increase of 30.1% from $711.4 million year-over-year[147]. - Total operating expenses for the three months ended March 31, 2024, were $2,393.6 million, an increase of 8.0% from $2,215.4 million in the same period of 2023[151]. - Cash flows provided by operating activities were $1,512.5 million for the three months ended March 31, 2024, an increase of $144.9 million from $1,367.6 million in the same period of 2023[165]. - Cash flows used in investing activities significantly increased to $(1,687.1) million in Q1 2024, compared to $(235.7) million in Q1 2023, indicating a change of $(1,451.4) million[165]. - As of March 31, 2024, the company had cash and cash equivalents of $2,602.0 million, down from $2,730.0 million at the end of 2023, a decrease of $128.0 million[164]. - The company reported unrealized losses on equity securities of $(196.2) million for Q1 2024, compared to $(164.7) million in Q1 2023[159]. - The effective tax rate for the three months ended March 31, 2024, was (3.0%), compared to 4.7% in the same period of 2023, positively impacted by stock-based compensation and income earned in lower-tax jurisdictions[161]. Product Development and Pipeline - The company continues to focus on developing treatments for serious diseases, including eye diseases, cancer, and rare diseases, leveraging its integrated biotechnology capabilities[104]. - Regeneron emphasizes the importance of maintaining a strong foundation in scientific research and discovery-enabling technologies to support its product pipeline[104]. - The company is actively pursuing regulatory approvals for its late-stage product candidates, which may impact future revenue streams[105]. - The company plans to initiate a Phase 3 study for EYLEA HD in RVO by mid-2024 and submit a supplemental Biologics License Application for wAMD and DME[116]. - Dupixent has received FDA approval for EoE in pediatrics, with an EC decision on regulatory submission expected in the second half of 2024[116]. - The company anticipates a decision from the FDA on the sBLA for Dupixent by June 27, 2024, and an EC decision for COPD regulatory submission in the second half of 2024[117]. - Upcoming milestones include reporting results from ongoing Phase 3 trials in CSU and bullous pemphigoid in late 2024[117]. - The company is developing multiple product candidates in clinical phases, with uncertainties related to safety, efficacy, and regulatory requirements impacting timelines[113]. - The company initiated a Phase 1 study of linvoseltamab in combination with dupilumab for severe food allergy in 2024[123]. - The company is expected to report results from the Phase 2 study of REGN9933 in thrombosis in the second half of 2024[119]. - The company plans to report initial data from the Phase 2/3 study in first-line advanced NSCLC in the second half of 2024[118]. - The company has a target action date of August 22, 2024, for the FDA decision on the BLA for relapsed/refractory multiple myeloma[118]. - The company will present updated data from the Phase 1/2 trial of DB-OTO at the May 2024 ASGCT annual conference[123]. - The company has expanded its collaboration with Intellia to develop additional in vivo CRISPR-based gene editing therapies[132]. Collaborations and Partnerships - Regeneron collaborates with Bayer and Sanofi for various products, which may influence market expansion and product availability[109]. - The company has a contingent reimbursement obligation to Sanofi of approximately $2.200 billion as of March 31, 2024, related to development expenses[124]. - The company authorized a new share repurchase program in April 2024 to repurchase up to an additional $3.0 billion of its common stock, with $1.233 billion remaining available under the previous program as of March 31, 2024[169]. - Collaboration revenue from Bayer was $356.0 million, slightly down from $356.9 million in the prior year[148]. - Regeneron's share of profits in connection with commercialization of antibodies increased to $804.0 million, up 26.3% from $636.5 million year-over-year[144]. Operational and Regulatory Considerations - Ongoing regulatory obligations and potential delays from governmental authorities could affect the commercialization of Regeneron's products[105]. - The company is focused on managing supply chains effectively to ensure the availability of its products in the market[105]. - Total direct research and development expenses for the three months ended March 31, 2024, were $408.3 million, an increase of 85.9 million or 26.7% compared to $322.4 million in the same period of 2023[154]. - Total research and development expenses, including stock-based compensation, amounted to $1,248.4 million for the three months ended March 31, 2024, up from $1,101.2 million in 2023, reflecting an increase of $147.2 million or 13.4%[154]. - Selling, general, and administrative expenses increased due to commercialization-related expenses for EYLEA HD and higher headcount costs, totaling $86.2 million in stock-based compensation for Q1 2024, compared to $76.8 million in Q1 2023[155]. - The company conducted an evaluation of its disclosure controls and procedures, concluding they were effective as of the end of the reporting period[175]. - There were no changes in internal control over financial reporting during the quarter ended March 31, 2024, that materially affected or are likely to affect internal controls[176]. - The company referenced its market risks and management strategies in its Annual Report on Form 10-K for the fiscal year ended December 31, 2023, with no material changes noted as of March 31, 2024[173].

Exhibit 99.1 Press Release Regeneron Reports First Quarter 2024 Financial and Operating Results • First quarter 2024 revenues decreased 1% to $3.15 billion versus first quarter 2023; excluding RonapreveTM(a)(b), revenues increased 7% • First quarter 2024 Dupixent® global net sales (recorded by Sanofi) increased 24% to $3.08 billion versus first quarter 2023 • First quarter 2024 U.S. net sales for EYLEA® HD and EYLEA® were $1.40 billion, including $200 million from EYLEA HD • First quarter 2024 Libtayo® glob ...

Biotech giant Regeneron Pharmaceuticals, Inc. (REGN) is slated to report first-quarter results on May 2, 2024.Once a rock-solid biotech stock to invest in, Regeneron is currently facing challenges for its lead drug, Eylea, which is its primary growth engine.  These challenges are likely to have negatively impacted the upcoming results.The Zacks Consensus Estimate for REGN’s first-quarter revenues is pegged at $3.2 billion, while the same for earnings is pinned at $10.20 per share.Decline in Eylea SalesA sig ...

A downtrend has been apparent in Regeneron (REGN) lately with too much selling pressure. The stock has declined 8.2% over the past four weeks. However, given the fact that it is now in oversold territory and Wall Street analysts are majorly in agreement about the company's ability to report better earnings than they predicted earlier, the stock could be due for a turnaround.How to Determine if a Stock is OversoldWe use Relative Strength Index (RSI), one of the most commonly used technical indicators, for sp ...

The upcoming report from Regeneron (REGN) is expected to reveal quarterly earnings of $10.14 per share, indicating an increase of 0.5% compared to the year-ago period. Analysts forecast revenues of $3.19 billion, representing an increase of 0.8% year over year.The consensus EPS estimate for the quarter has been revised 2.5% higher over the last 30 days to the current level. This reflects how the analysts covering the stock have collectively reevaluated their initial estimates during this timeframe.Prior to ...

TARRYTOWN, N.Y., April 29, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) today announced the presentation of positive long-term results and subgroup analyses from the pivotal clinical program of EYLEA® HD (aflibercept) Injection 8 mg. The presentations are part of 14 accepted abstracts on EYLEA HD and EYLEA® (aflibercept) Injection 2 mg that will be shared at the Association for Research in Vision and Ophthalmology (ARVO) annual meeting from May 5 to 9 in Seattle. "Our extensive dat ...

Mammoth's proprietary ultracompact CRISPR-based gene editing platform and Regeneron's proprietary delivery technologies set to advance in vivo programs in multiple tissue and cell types Mammoth to receive $100 million total upfront payment and equity investment from Regeneron at signing TARRYTOWN, N.Y., April 25, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) and Mammoth Biosciences, Inc., today announced a collaboration to research, develop and commercialize in vivo CRISPR-based gen ...

Oral presentations include updated results from clinical study of otoferlin gene therapy DB-OTO demonstrating restoration in children with profound genetic hearing loss Additional presentations cover progress in novel genetic medicine delivery systems and immune response modulation TARRYTOWN, N.Y., April 22, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) today announced that new and updated data across its genetic medicines portfolio will be presented at the American Society of Gene ...